The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
ELI LILLY AND COMPANY 8.83 BOSTON SCIENTIFIC CORPORATION 7.50 INTUITIVE SURGICAL INC 5.22 ABBVIE INC 4.68 UNITEDHEALTH GROUP INC 4.46 Name Weight (%) ABBOTT LABORATORIES 4.01 STRYKER CORPORATION 3.32 DANAHER CORPORATION 3.14 THERMO FISHER SCIENTIFIC INC 3.00 GILEAD SCIENCES INC 2.65 Det...
DehydraTECH™ is Lexaria’s patented drug delivery-enabling platform technology which improves the absorption of active pharmaceutical ingredients (APIs) into the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of API’s mainly in oral f...
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid Karen Andersen, CFAFeb 7, 2025 Roblox Earnings: Disappointing Engagement and Weak Forecast for Profitability Improvement Matthew Dolgin, CFAFeb 7, 2025 Cognizant Earnings: Large Deal Momentum Drives Top-Line Growth ...
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid Karen Andersen, CFAFeb 7, 2025 Roblox Earnings: Disappointing Engagement and Weak Forecast for Profitability Improvement Matthew Dolgin, CFAFeb 7, 2025 Cognizant Earnings: Large Deal Momentum Drives Top-Line Growth ...
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid Karen Andersen, CFAFeb 7, 2025 Roblox Earnings: Disappointing Engagement and Weak Forecast for Profitability Improvement Matthew Dolgin, CFAFeb 7, 2025 Cognizant Earnings: Large Deal Momentum Drives Top-Line Growth ...
Eli Lilly Receives FDA Approval for Crohn's Disease Treatment Global News SelectJan 16, 2025 5:40am DJIA Rises 1.65% to 43221.55 — Data Talk Global News SelectJan 16, 2025 5:29am NASDAQ Composite Rises 2.45% to 19511.23 — Data Talk ...
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid Karen Andersen, CFA Feb 7, 2025 Roblox Earnings: Disappointing Engagement and Weak Forecast for Profitability Improvement Matthew Dolgin, CFA Feb 7, 2025 Cognizant Earnings: Large Deal Momentum Drives Top-Line Growth Eric Compton, CFA Feb 6...
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid Karen Andersen, CFAFeb 7, 2025 Roblox Earnings: Disappointing Engagement and Weak Forecast for Profitability Improvement Matthew Dolgin, CFAFeb 7, 2025 Funds View All The Best Small-Cap ETFs ...
Eli Lilly and Co Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat Karen Andersen, CFAFeb 7, 2025 Rating Price $872.19 Fair Value $620.00 Uncertainty High Economic Moat Wide Capital Allocation ...